Want to see CC full AI Analyst Report?
Top Page
Chemours Company
(NYSE:CC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$14.00
▼(-17.55% Downside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by weakened financial performance (sharp revenue decline, losses, and a highly stressed capital structure with negative equity) and bearish technicals (below key moving averages with negative MACD). Offsetting these, earnings call guidance points to improving EBITDA/FCF and leverage reduction, and the dividend provides modest support, but near-term demand and cost headwinds still limit upside.
Positive Factors
TiO2 pricing actions
Repeated pricing actions show management is addressing weak Titanium Technologies economics and may help rebuild margins. If sustained, improved pricing can offset input inflation and support earnings recovery despite softer volumes.
Negative Factors
Severe revenue and profitability deterioration
The sharp sales decline and near-zero EBITDA profitability indicate that Chemours remains vulnerable to weak industrial demand, lower utilization and cost inflation. A sustained earnings recovery depends on restoring volumes, pricing and margins across multiple segments.
Read all positive and negative factors
Positive Factors
Negative Factors
TiO2 pricing actions
Repeated pricing actions show management is addressing weak Titanium Technologies economics and may help rebuild margins. If sustained, improved pricing can offset input inflation and support earnings recovery despite softer volumes.
Read all positive factors
Chemours Company Key Performance Indicators (KPIs)
Any
Adjusted EBITDA by Segment
Profitability by business unit after removing one-time items, showing which segments generate the most cash and the strongest margins. Highlights where pricing power or cost control is working, where earnings are vulnerable to raw-material or energy price swings, and which divisions are most important for sustaining free cash flow.
Profitability by business unit after removing one-time items, showing which segments generate the most cash and the strongest margins. Highlights where pricing power or cost control is working, where earnings are vulnerable to raw-material or energy price swings, and which divisions are most important for sustaining free cash flow.
Data provided by:
The Fly
The FlyChemours Company (CC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.36B
Dividend Yield2.19%
Average Volume (3M)2.52M
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue Growth-1.38%
EPS Growth28.10%
CountryUS
Employees5,700
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-2.40
Shares Outstanding150,499,000
10 Day Avg. Volume2,150,553
30 Day Avg. Volume2,522,722
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)7.09
Price to Sales (P/S)0.31
P/FCF Ratio34.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.78Price Target Upside16.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)1.08
Revenue Forecast (FY)$5.95B
Chemours Company Business Overview & Revenue Model
Company Description
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Ad...
How the Company Makes Money
Chemours makes money primarily by manufacturing chemical products and selling them to customers globally, with revenue recognized largely from product sales under supply agreements and purchase orders. Its key revenue streams are aligned to its op...
Chemours Company Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 28, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful operational and commercial progress—Q2 adjusted EBITDA beat expectations, TT pricing momentum (≈5% YTD), APM Performance Solutions growth (+8% YoY) and strong cash generation including a ~$270M debt repayment—while also acknowledging notable near-term headwinds, especially TSS aftermarket destocking (pre-buy impact ≈$65M and ~25% YoY market drop), APM volume effects from a prior line closure and TT volume softness amid inflationary input costs. Management reiterated a constructive multi-year view (Pathway to Thrive, $1B adjusted EBITDA ambition) and provided a measured FY 2026 outlook, but near-term guidance incorporates expected sequential declines and ongoing uncertainties.Positive Updates
Q2 Adjusted EBITDA Outperformance and Pricing Momentum
Adjusted EBITDA exceeded expectations in Q2 driven by stronger operational performance, an improved product mix in APM and pricing gains in Titanium Technologies; company announced three TiO2 price increases since December 2025, contributing to approximately a 5% year-to-date price increase in TT.
Negative Updates
TSS Aftermarket Destocking and Softer Residential Demand
Net sales were slightly below expectations primarily due to weaker residential stationary AC aftermarket demand; management cited distributor channel pre-buys in 2025 (estimated at about $65 million of sales that shifted timing) and noted the stationary aftermarket market size is down roughly 25% year-over-year, with destocking and macro affordability headwinds likely to pressure near-term order activity.
Read all updates
Q2-2026 Updates
Positive
Negative
Q2 Adjusted EBITDA Outperformance and Pricing Momentum
Adjusted EBITDA exceeded expectations in Q2 driven by stronger operational performance, an improved product mix in APM and pricing gains in Titanium Technologies; company announced three TiO2 price increases since December 2025, contributing to approximately a 5% year-to-date price increase in TT.
Read all positive updates
Company Guidance
Chemours guided Q3 consolidated net sales to be down 5% to flat sequentially with consolidated adjusted EBITDA of $175–$205 million, corporate expense of ~$40–$45 million, Q3 CapEx of ~$65 million and at least $50 million of free cash flow; segment guidance was TSS net sales down sequentially mid‑teens to 20% with adjusted EBITDA $125–$140 million, TT net sales up low‑ to mid‑single digits with adjusted EBITDA $70–$80 million, and APM net sales up mid‑ to high‑single digits with adjusted EBITDA $20–$30 million. For full‑year 2026 Chemours expects net sales +1% to +5% versus 2025, adjusted EBITDA $775–$825 million, CapEx $250–$280 million, free cash flow conversion above 25% and net leverage around 3.8x by year‑end; management also reiterated longer‑term targets of at least $1.0 billion of annual adjusted EBITDA and >40% FCF conversion and noted TT pricing actions have driven roughly a 5% YTD TiO2 price increase.Chemours Company Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.80B | 5.81B | 5.78B | 6.08B | 6.83B | 6.34B |
| Gross Profit | 889.00M | 902.00M | 1.15B | 1.31B | 1.62B | 1.38B |
| EBITDA | -166.00M | 332.00M | 692.00M | 197.00M | 1.20B | 1.18B |
| Net Income | -304.00M | -386.00M | 86.00M | -238.00M | 578.00M | 608.00M |
Balance Sheet | ||||||
| Total Assets | 7.15B | 7.38B | 7.51B | 8.25B | 7.64B | 7.55B |
| Cash, Cash Equivalents and Short-Term Investments | 671.00M | 672.00M | 713.00M | 1.20B | 1.10B | 1.45B |
| Total Debt | 4.12B | 4.58B | 4.36B | 4.30B | 3.88B | 3.99B |
| Total Liabilities | 7.20B | 7.13B | 6.91B | 7.51B | 6.53B | 6.47B |
| Stockholders Equity | -49.00M | 250.00M | 604.00M | 737.00M | 1.11B | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | 125.00M | 51.00M | -993.00M | 186.00M | 448.00M | 537.00M |
| Operating Cash Flow | 353.00M | 264.00M | -633.00M | 556.00M | 755.00M | 814.00M |
| Investing Cash Flow | 73.00M | -206.00M | -353.00M | -229.00M | -284.00M | 220.00M |
| Financing Cash Flow | -369.00M | -126.00M | -36.00M | 172.00M | -686.00M | -554.00M |
Chemours Company Technical Analysis
Neutral
16.98
Price Trends
17.99
Negative
20.54
Negative
17.79
Negative
Market Momentum
-0.65
Negative
46.51
Neutral
75.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CC, the sentiment is Neutral. The current price of 16.98 is above the 20-day moving average (MA) of 15.90, below the 50-day MA of 17.99, and below the 200-day MA of 17.79, indicating a neutral trend. The MACD of -0.65 indicates Negative momentum. The RSI at 46.51 is Neutral, neither overbought nor oversold. The STOCH value of 75.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CC.
Chemours Company Risk Analysis
Chemours Company disclosed 40 risk factors in its most recent earnings report. Chemours Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chemours Company Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $2.29B | 19.07 | 9.15% | 2.11% | 2.87% | 534.76% | |
66 Neutral | $2.84B | 28.96 | 7.12% | 1.34% | 7.79% | ― | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | $3.33B | 63.74 | 2.77% | 2.51% | -1.39% | ― | |
59 Neutral | $2.38B | 45.63 | 85.17% | ― | -12.42% | ― | |
47 Neutral | $2.12B | -14.96 | -7.67% | 3.45% | 0.60% | -920.33% | |
44 Neutral | $2.36B | -7.99 | -170.31% | 2.06% | -1.38% | 28.10% |
* Basic Materials Sector Average
CC
Chemours Company
15.97
0.93
6.16%
ASH
Ashland
72.66
17.73
32.27%
IOSP
Innospec
93.63
7.56
8.78%
OLN
Olin
18.40
-4.01
-17.90%
KWR
Quaker Chemical
163.02
20.35
14.26%
NGVT
Ingevity
70.27
12.48
21.60%
Chemours Company Corporate Events
Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance
Chemours Reaches Major PFAS Settlement and Compliance Agreement
Negative
Jun 24, 2026
On June 23, 2026, Chemours agreed to a proposed consent decree with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims over PFAS emissions and other alleged non-compliance at its...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.